Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Andrew R. Blight, Ph.D., Acorda’s Chief Scientific Officer, and Tierney Saccavino, Senior Vice President, Corporate Communications, will present at the JMP Healthcare Conference on Wednesday, July 10 at 11:30 a.m. at the St. Regis Hotel in New York.
A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com or you may use the link:
Please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection. Archived versions of this webcast will be available until August 10 on the Investors section of www.acorda.com.About Acorda Therapeutics Acorda Therapeutics is a biotechnology company focused on developing therapies that restore, repair and improve neurological function for patients living with nervous system disorders. The Company currently markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is manufactured by Alkermes Pharma Ireland Limited. The Company also markets ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda also receives sales royalties on tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES, distributed by Actavis, Inc. under its agreement with Acorda. Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is developing Diazepam Nasal Spray for treatment of certain epileptic seizures. It is also studying AMPYRA to improve a range of functional impairments caused by MS, as well as its potential for use in other neurological conditions, including cerebral palsy and post-stroke deficits. In addition, Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury, GGF2 for treatment of heart failure and rHIgM22, a remyelinating monoclonal antibody, for the treatment of MS. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and peripheral nerve damage. Chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury, is in preclinical development.